Report: Target Atlas of Apoptopic Drugs & Focus on Lung Cancer & Melanoma TOC

1 Executive Summary

2 Methodologies

3 Table of Contents

3.1 List of Tables
3.2 List of Boxes
3.3 List of Figures

4 Introduction to Apoptotic Drugs in Oncology

5 Apoptopic Drug Compound Types and Sub-cellular Localizations of Targets

6 The Cancer Genome Project and Apoptopic Drug Targets

6.1 Apoptopic Drug Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer

7 Protein Expression Profiles of Apoptopic Drug Targets in Human

7.1 Expression in Normal Tissues and Cancer Tissues
7.2 Expression in Human Cancer Cell Lines and Primary Cells

8 Pathway Analysis of Drug Targets of Apoptopic Drugs

9 Protein-Protein Interactions Between Identified Apoptopic Drug Targets

10 Available Biological Structure Data on Apoptopic Drug Targets

11 Drug Target Profiles of Apoptopic Drug Targets in Oncology

11.1.1 Auxiliary transport protein activity
11.1.2 Carboxy-lyase activity
11.1.3 Catalytic activity
11.1.4 Cell adhesion molecule activity
11.1.5 Chaperone activity
11.1.6 Complement activity
11.1.7 Cysteine-type peptidase activity
11.1.8 Cytokine activity
11.1.9 DNA topoisomerase activity
11.1.10 Glutathione transferase activity
11.1.11 Hormone activity
11.1.12 Hydrolase activity
11.1.13 Intracellular ligand-gated ion channel activity
11.1.14 Kinase activity
11.1.15 Kinase regulator activity
11.1.16 Ligase activity
11.1.17 Lipid kinase activity
11.1.18 Metallopeptidase activity
11.1.19 Molecular function unknown
11.1.20 Motor activity
11.1.21 Oxidoreductase activity
11.1.22 Peptide hormone
11.1.23 Peroxidase activity
11.1.24 Protein binding
11.1.25 Protein serine/threonine kinase activity
11.1.26 Protein threonine/tyrosine kinase activity
11.1.27 Protein-tyrosine kinase activity
11.1.28 Receptor activity
11.1.29 Receptor binding
11.1.30 Receptor signaling complex scaffold activity
11.1.31 Receptor signaling protein serine/threonine kinase activity
11.1.32 RNA binding
11.1.33 Structural constituent of cytoskeleton
11.1.34 Superoxide dismutase activity
11.1.35 T cell receptor activity
11.1.36 Transcription factor activity
11.1.37 Transcription regulator activity
11.1.38 Transferase activity
11.1.39 Translation regulator activity
11.1.40 Transmembrane receptor activity
11.1.41 Transmembrane receptor protein tyrosine kinase activity
11.1.42 Transporter activity

12 Apoptopic Drug Target Mix by Development Stage

13 Apoptopic Drug Target Mix by Cancer Indication

13.1 Basal Cell Cancer
13.2 Biliary Cancer
13.3 Bladder Cancer
13.4 Bone Cancer
13.5 Brain Cancer
13.6 Breast Cancer
13.7 Carcinoid Tumor
13.8 Cervical Cancer
13.9 Chemotherapy-induced Neutropenia
13.10 Colorectal Cancer
13.11 Endometrial Cancer
13.12 Fallopian Tube Cancer
13.13 Gastrointestinal Cancer
- 13.13.1 Gastrointestinal Stomach Cancer
- 13.13.2 Gastrointestinal Stromal Cancer
13.14 Head and Neck Cancer
13.15 Leukemia
- 13.15.1 Acute Lymphocytic Leukemia
- 13.15.2 Acute Myelogenous Leukemia
- 13.15.3 Chronic Lymphocytic Leukemia
- 13.15.4 Chronic Myelogenous Leukemia
13.16 Liver Cancer
13.17 Lung Cancer
- 13.17.1 Non-Small Cell Lung Cancer
- 13.17.2 Small Cell Lung Cancer
13.18 Lymphoma
- 13.18.1 B-cell Lymphoma
- 13.18.2 Hodgkin' s Lymphoma
- 13.18.3 non-Hodgkin' s Lymphoma
- 13.18.4 T-cell Lymphoma
13.19 Melanoma
13.20 Mesothelioma
13.21 Myelodysplastic Syndrome
13.22 Myeloma
13.23 Nasopharyngeal Cancer
13.24 Oesophageal Cancer
13.25 Oral Cancer
13.26 Ovarian Cancer
13.27 Pancreatic Cancer
13.28 Peritoneal Cancer
13.29 Prostate Cancer
13.30 Renal Cancer
13.31 Sarcoma
- 13.31.1 Leiomyo Sarcoma
13.32 Squamous Cell Cancer
13.33 Testicular Cancer
13.34 Thymoma Cancer
13.35 Thyroid Cancer

14 Apoptopic Drugs and their Targets by Companies

14.1 Australia
14.2 Canada
14.3 China
14.4 Denmark
14.5 Germany
14.6 Israel
14.7 Japan
14.8 South Korea
14.9 Spain
14.10 Switzerland
14.11 Taiwan
14.12 United Kingdom
14.13 USA

15 Lung cancer: An Introduction

15.1 Current Treatment Strategies
15.2 Disease Definition
15.3 Etiology & Pathophysiology
15.4 Prognosis
15.5 Epidemiology

16 Progress in Current Lung Cancer Treatment Strategies

16.1 Improvements Adding microtubule Inhibitor
16.2 Improvement of Disease Related Symptoms in Elderly Patients
16.3 Toxicity Profile Favored
16.4 A New Formula
16.5 Monotherapy?
16.6 Failed to Demonstrate a Survival Advantage
16.7 Reduction in Mortality Risk

17 Key Drug Strategies in Lung Cancer

17.1 Apoptosis
17.2 Antiangiogenesis and Antivascular Agents
- 17.2.1 EGFR and VEGFR as target
- 17.2.2 Immunotherapy

18 Competitive Landscape in Lung Cancer Drug Development: The Late Stage Pipeline

18.1 Grade 4 Adverse Events
18.2 No New Remarks
18.3 No Significant Effect on Overall Survival
18.4 Bristol Myers Squibb Entered into an Agreement
18.5 Many Uncertainties Remain
18.6 Development Terminated
18.7 Continuing Enrollment
18.8 Apoptotic Inducer
18.9 Fully-Human Monoclonal Antibody
18.10 Eagerly Awaiting Data
18.11 Mutations and Response
18.12 Statistically and Clinically Significant Survival Advantage
18.13 Anti-Idiotypic Monoclonal Antibody
18.14 Shift in the Development Focus
18.15 Sensitizer
18.16 Treatment in Earlier-Stage Cancer Could be More Effective
18.17 Discontinued Radiosensitizer
18.18 Improvement in Chemoradiotherapy
18.19 Progress on HDAC Inhibitor
18.20 Progress Analysis Carboxyamidotriazole
18.21 Chemotherapy naïve subjects

19 Etiology and Pathophysiology of Melanoma

20 Current Melanoma Treatment Strategies

20.1 An Overview
20.2 Cytotoxic Drugs
- 20.2.1 Dacarbazine
- 20.2.2 Cisplatin
- 20.2.3 Carboplatin
- 20.2.4 Carmustine
- 20.2.5 Melphalan
- 20.2.6 Paclitaxel
- 20.2.7 Tamoxifen
- 20.2.8 Temozolomide
- 20.2.9 Vinblastine/Vinorelbine
20.3 Biological treatments
- 20.3.1 Intron A
- 20.3.2 Virulizin
- 20.3.3 Melacine
- 20.3.4 Alfanative (Multiferon)
- 20.3.5 Proleukin or (Macrolin)
- 20.3.6 Enhanzyn
- 20.3.7 M-VAX
20.4 Other
- 20.4.1 Ceplene Maxamine

21 Key Melanoma Therapy Strategies

21.1 Immunotherapy
21.2 Anti-angiogenesis
21.3 Apoptotic Induction
21.4 Gene Therapy

22 Current Melanoma Drug Development: Late Stage Pipeline

22.1 Immunotherapy
- 22.1.1 Oncophage
- 22.1.2 Canvaxin
- 22.1.3 GMK
- 22.1.4 MDX-010
- 22.1.5 OncoVax
- 22.1.6 ALLOVECTIN-7
- 22.1.7 Peginterferon alfa-2b
22.2 Anti-angiogenesis
- 22.2.1 Lenalidomide
22.3 Apoptotic Inducers
- 22.3.1 Genasense
22.4 Inhibiting Cell Growth
- 22.4.1 Temozolomide

23 Current Melanoma Drug Development: Early Stage Pipeline

23.1 Immunotherapy
- 23.1.1 INGN 241
- 23.1.2 QS-21
- 23.1.3 Talabostat
- 23.1.4 SB 249553
- 23.1.5 GVAX
- 23.1.6 GV 1001
- 23.1.7 Dexosome
- 23.1.8 Uvidem
- 23.1.9 NY-ESO-1 ISCOMS
- 23.1.10 NOVOVAC-M1
- 23.1.11 Oxxon Vaccine
- 23.1.12 Therion' s Melanoma Vaccine
- 23.1.13 ImmunoVex trimelan
- 23.1.14 OncoVEXGM-CSF
- 23.1.15 Zadaxin
- 23.1.16 Alvac-Mage1/Mage3
- 23.1.17 Iboctadekin
- 23.1.18 ProMune
- 23.1.19 BAY 504798
- 23.1.20 EMD 273063
23.2 Antiangiogenesis
- 23.2.1 Sorafenib
- 23.2.2 Vitaxin
- 23.2.3 Avastin
- 23.2.4 PI 88
23.3 Apoptotic Inducers
- 23.3.1 Didemnin B
- 23.3.2 KOS 953
23.4 Small Molecules Inhibiting Cell Growth
- 23.4.1 Pivanex
- 23.4.2 Karenitecin
- 23.4.3 Lomeguatrib
- 23.4.4 PD 0325901
- 23.4.5 SB 715992
- 23.4.6 INO 1001
- 23.4.7 CP 4055
23.5 Other Biological Drugs
- 23.5.1 AP 12009
- 23.5.2 Ecromeximab
- 23.5.3 ILX 651
- 23.5.4 Kahalalide F
- 23.5.5 ABX MA1
- 23.5.6 MJV 101
- 23.5.7 A Russian Melanoma Vaccine
- 23.5.8 Elea Vaccine
- 23.5.9 F 50040

24 Appendix 1. Treatment Guide Lines Lung Cancer*

24.1 References

25 Appendix 2: Selected Company Profiles

25.1 Abgenix
25.2 Aphton
25.3 AstraZeneca
25.4 Bristol-Myers Squibb
25.5 Eli Lilly
25.6 Genentech
25.7 Genta
25.8 GlaxoSmithKline
25.9 ImClone
25.10 ISIS Pharmaceuticals
25.11 Ligand Pharmaceuticals
25.12 OSI Pharmaceuticals
25.13 Pfizer
25.14 Pharmacyclics
25.15 Sanofi- Aventis
25.16 Telik

26 Appendix 3 Progress profiles on approved drugs

26.1 Docetaxel
26.2 Vinorelbine
26.3 Gemcitabine
26.4 Paclitaxel
26.5 Pemetrexed
26.6 Gefitinib
26.7 Erlotinib

27 Appendix 4: Treatment Guide Lines Melanoma

28 Disclaimer

29 Drug Index

30 Company Index

List of Tables

Table 1: Compound Type Versus Primary and Alternate Localization of Drug Target
Table 2: Drug Targets of Apoptopic Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census
Table 3: Available Protein Expression Profiles of Apoptopic Drug Targets
Table 4: Pathway Summary
Table 5: Drug Targets Without any Identified Assigned Pathways
Table 6: Pathway Profile According to BioCarta of the Drug Targets Belonging to Apoptopic Drugs
Table 7: Drug Targets Belonging to Apoptopic Pathways According to BioCarta
Table 8: Pathway Profile According to KEGG of the Drug Targets Belonging to Apoptopic Drugs
Table 9: Drug Targets within the Apoptosis Pathway According to KEGG
Table 10: Apoptopic Drugs Targeting Major Singaling Pathways
Table 11: Protein-Protein Interactions Between Identified Apoptopic Drug Targets
Table 12: Targets of Apoptopic Drugs without Protein-Protein Interaction with other Drug Targets
Table 13: Number of Available Biological Structures on Apoptopic Drug Targets
Table 14: Overview of Drug Target Profile Themes
Table 15: Fall Out in Terms of the Number of Drug Target Mixes, Drugs, and Developmental Projects by Developmental Stage
Table 16: Apoptopic Drug Target Mixes by Development
Table 17: Number of Unique Apoptopic Drug Target Mixes Reported by Cancer Indication
Table 18: Apoptopic Drug Target Mix for the Treatment of Basal Cell Cancer According to the Compound Type and Developmental Stage of Drug
Table 19: Apoptopic Drug Target Mix for the Treatment of Biliary Cancer According to the Compound Type and Developmental Stage of Drug
Table 20: Apoptopic Drug Target Mix for the Treatment of Bladder Cancer According to the Compound Type and Developmental Stage of Drug
Table 21: Apoptopic Drug Target Mix for the Treatment of Bone Cancer According to the Compound Type and Developmental Stage of Drug
Table 22: Apoptopic Drug Target Mix for the Treatment of Brain Cancer According to the Compound Type and Developmental Stage of Drug
Table 23: Apoptopic Drug Target Mix for the Treatment of Breast Cancer According to the Compound Type and Developmental Stage of Drug
Table 24: Apoptopic Drug Target Mix for the Treatment of Carcinoid Tumor According to the Compound Type and Developmental Stage of Drug
Table 25: Apoptopic Drug Target Mix for the Treatment of Cervical Cancer According to the Compound Type Developmental Stage of Drug
Table 26: Apoptopic Drug Target Mix for the Treatment of Chemotherapy-induced Neutropenia According to the Compound Type and Developmental Stage of Drug
Table 27: Apoptopic Drug Target Mix for the Treatment of Colorectal Cancer According to the Compound Type and Developmental Stage of Drug
Table 28: Apoptopic Drug Target Mix for the Treatment of Endometrial Cancer According to the Compound Type and Developmental Stage of Drug
Table 29: Apoptopic Drug Target Mix for the Treatment of Fallopian Tube Cancer According to the Compound Type and Developmental Stage of Drug
Table 30: Apoptopic Drug Target Mix for the Treatment of Gastrointestinal Cancer According to the Compound Type and Developmental Stage of Drug
Table 31: Apoptopic Drug Target Mix for the Treatment of Gastrointestinal Stomach Cancer According to the Compound Type and Developmental Stage of Drug
Table 32: Apoptopic Drug Target Mix for the Treatment of Gastrointestinal Stromal Cancer According to the Compound Type and Developmental Stage of Drug
Table 33: Apoptopic Drug Target Mix for the Treatment of Head and Neck Cancer According to the Compound Type and Developmental Stage of Drug
Table 34: Apoptopic Drug Target Mix for the Treatment of Leukemia (general) According to the Compound Type and Developmental Stage of Drug
Table 35: Apoptopic Drug Target Mix for the Treatment of Acute Lymphocytic Leukemia According to the Compound Type and Developmental Stage of Drug
Table 36: Apoptopic Drug Target Mix for the Treatment of Acute Myelogenous Leukemia According to the Compound Type and Developmental Stage of Drug
Table 37: Apoptopic Drug Target Mix for the Treatment of Chronic Lymphocytic Leukemia According to the Compound Type and Developmental Stage of Drug
Table 38: Apoptopic Drug Target Mix for the Treatment of Chronic Myelogenous Leukemia According to the Compound Type and Developmental Stage of Drug
Table 39: Apoptopic Drug Target Mix for the Treatment of Liver Cancer According to the Compound Type and Developmental Stage of Drug
Table 40: Apoptopic Drug Target Mix for the Treatment of Lung Cancer (general) According to the Compound Type and Developmental Stage of Drug
Table 41: Apoptopic Drug Target Mix for the Treatment of Non-Small Cell Lung Cancer According to the Compound Type and Developmental Stage of Drug
Table 42: Apoptopic Drug Target Mix for the Treatment of Small Cell Lung Cancer According to the Compound Type and Developmental Stage of Drug
Table 43: Apoptopic Drug Target Mix for the Treatment of Lymphoma (general) According to the Compound Type and Developmental Stage of Drug
Table 44: Apoptopic Drug Target Mix for the Treatment of B-cell Lymphoma According to the Compound Type and Developmental Stage of Drug
Table 45: Apoptopic Drug Target Mix for the Treatment of Hodgkin' s Lymphoma According to the Compound Type and Developmental Stage of Drug
Table 46: Apoptopic Drug Target Mix for the Treatment of non-Hodgkin' s Lymphoma According to the Compound Type and Developmental Stage of Drug
Table 47: Apoptopic Drug Target Mix for the Treatment of T-cell Lymphoma According to the Compound Type and Developmental Stage of Drug
Table 48: Apoptopic Drug Target Mix for the Treatment of Melanoma According to the Compound Type and Developmental Stage of Drug
Table 49: Apoptopic Drug Target Mix for the Treatment of Mesothelioma According to the Compound Type and Developmental Stage of Drug
Table 50: Apoptopic Drug Target Mix for the Treatment of Myelodysplastic Syndrome According to the Compound Type and Developmental Stage of Drug
Table 51: Apoptopic Drug Target Mix for the Treatment of Myeloma According to the Compound Type and Developmental Stage of Drug
Table 52: Apoptopic Drug Target Mix for the Treatment of Nasopharyngeal Cancer According to the Compound Type and Developmental Stage of Drug
Table 53: Apoptopic Drug Target Mix for the Treatment of Oesophageal Cancer According to the Compound Type and Developmental Stage of Drug
Table 54: Apoptopic Drug Target Mix for the Treatment of Oral Cancer According to the Compound Type and Developmental Stage of Drug
Table 55: Apoptopic Drug Target Mix for the Treatment of Ovarian Cancer According to the Compound Type and Developmental Stage of Drug
Table 56: Apoptopic Drug Target Mix for the Treatment of Pancreatic Cancer According to the Compound Type and Developmental Stage of Drug
Table 57: Apoptopic Drug Target Mix for the Treatment of Peritoneal Cancer According to the Compound Type and Developmental Stage of Drug
Table 58: Apoptopic Drug Target Mix for the Treatment of Prostate Cancer According to the Compound Type and Developmental Stage of Drug
Table 59: Apoptopic Drug Target Mix for the Treatment of Renal Cancer According to the Compound Type and Developmental Stage of Drug
Table 60: Apoptopic Drug Target Mix for the Treatment of Sarcoma (general) According to the Compound Type and Developmental Stage of Drug
Table 61: Apoptopic Drug Target Mix for the Treatment of Leiomyo Sarcoma According to the Compound Type and Developmental Stage of Drug
Table 62: Apoptopic Drug Target Mix for the Treatment of Squamous Cell Cancer According to the Compound Type and Developmental Stage of Drug
Table 63: Apoptopic Drug Target Mix for the Treatment of Testiculat Cancer According to the Compound Type and Developmental Stage of Drug
Table 64: Apoptopic Drug Target Mix for the Treatment of Thymoma Cancer According to the Compound Type and Developmental Stage of Drug
Table 65: Apoptopic Drug Target Mix for the Treatment of Thyroid Cancer According to the Compound Type and Developmental Stage of Drug
Table 66: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Australia
Table 67: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Canada
Table 68: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in China
Table 69: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Denmark
Table 70: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Germany
Table 71: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Israel
Table 72: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Japan
Table 73: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in South Korea
Table 74: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Spain
Table 75: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Switzerland
Table 76: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Taiwan
Table 77: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in United Kingdom
Table 78: Apoptopic Drugs with Target Mix and Developmental Projects by Company in USA
Table 64: Chemotherapeutic drugs for treatment of NSCLC
Table 65. Near Term Approved Drugs for the Treatment of NSCLC
Table 66: Chemotherapy Drugs off Patent
Table 67: Generalized Illustration, Depicting the Key Elements Involved in the Apoptotic Pathways.
Table 68: VTA agents under development
Table 69: EGFR or VEGFR inhibitors
Table 70: FMS-like tyrosine kinases and their Synonyms
Table 71: Fms-related Tyrosine Kinase Targets in Development
Table 72: Protein Kinase Targets in Clinical Trials for Lung Cancer
Table 73: Cancer immunotherapy strategies
Table 74: Recently presented studies Lapatinib
Table 75: Recently presented studies ZD-6474
Table 76: Recently presented studies vinflunine
Table 77: Recently presented studies Panitumumab
Table 78: Recently presented studies Genasense
Table 79: Recently presented studies cetuximab
Table 80: Recently presented studies bevacizumab
Table 81: Recently presented studies bexarotene
Table 82: Recently presented studies Xcytrin
Table 83: Critical Risk Factors for Development of Melanoma
Table 84: Definition and Description of Stages of Melanoma
Table 85: Prognosis of the 4 Stages of Malignant Melanoma
Table 86: Current Cytotoxic Drugs for the Treatment of Melanoma
Table 87: Progress Profile Dacarbazine
Table 88: Progress Profile Cisplatin
Table 89: Progress Profile Carboplatin
Table 90: Progress Profile Carmustine
Table 91: Progress Profile Melphalan
Table 92: Progress Profile Paclitaxel
Table 93: Progress Profile Tamoxifen
Table 94: Progress Profile Temozolomide
Table 95: Progress Profile Vinblastine/Vinorelbine
Table 96: Progress Profile Interferon alfa-2b
Table 97: Development Milestones- Virulizin
Table 98: Development Milestones - Melacine
Table 99: Development Milestones - Alfanative
Table 100: Development Milestones - Proleukin
Table 101: Deployed Strategies for Blocking Angiogenesis
Table 102: Phase III Randomized Studies of Melanoma Vaccines.
Table 103: Tumor antigen based vaccines
Table 104: In vivo Gene Therapy
Table 105: Cell Therapy Based Platform in Pipeline as Potential Treatment of Melanoma
Table 106: Ex vivo gene therapy loading of antigen presenting cells
Table 107: Overview of Immunostimulants in Development based on Type
Table 108: Overview of Immuno-Biologicals
Table 109: Overview of Gene Therapy Drugs for Immunostimulation
Table 110: MDX-010' s Collaborative History and Landscape
Table 111: Anti-angiogenisis Drugs under Development
Table 112: Overview Apoptopic Inducer Drugs
Table 113: Overview of Small Molecule Drugs
Table 114: Selected Regulatory Progress of Sorafenib
Table 115: Selected Regulatory Progress of Didemin B
Table 116: Overview of Various Biological Drugs in Development for Melanoma

List of Boxes

Box 1: Quick facts on Docetaxel
Box 2: Scientific Data on Docetaxel
Box 3: Quick Facts - Vinorelbine
Box 4: Scientific Data on Vinorelbine
Box 5: Quick Facts - Gemcitabine
Box 6: Scientific Data on gemcitabine
Box 7: Quick Facts - pemetrexed
Box 8: Scientific Data on Pemetrexed
Box 9: Quick Facts - Gefitinib
Box 10: Scientific Data on Gefitinib
Box 11: Quick Facts - Erlotinib
Box 12: Quick Facts - Enhanzyn
Box 13: Quick Facts - M-VAX
Box 14: M-VAX - Business & Market Bakground
Box 15: Mechanisms which Tumor Cells use to Evade an Immune Reaction
Box 16: Introgen' s INGN 241 Shows Vaccine Properties
Box 17: Quick Facts - Oncophage
Box 18: Oncophage - Designation and Status
Box 19: Quick Facts - Canvaxin
Box 20: Canvaxin - Designation and Status
Box 21: CancerVax Milestone payment
Box 22: Quick Facts - GM2-KLH Vaccine
Box 23: Progenics Reaquires Rights to Vaccine
Box 24: Completed Melanoma Phase III trials
Box 25: Quick Facts - MDX-010
Box 26: Quick Facts -OncoVax
Box 27: Quick Facts - ALLOVECTIN-7
Box 28: Quick Facts - Peginterferon alfa-2b
Box 29: Introgen' s INGN 241 Shows Anti-angiogenesis Properties
Box 30: Quick Facts - Lenalidomide
Box 31: Quick Facts - Oblimersen
Box 32: Quick Facts - Temozomide
Box 33: Molecular Pathways Underlying the Activity of Temozolomide' s Anti-Cancer Therapy
Box 34: Regulatory Progress
Box 35: Quick Facts - INGN 241
Box 36: Molecular Pathways Underlying Activity of Introgen' s INGN 241 Anti-Cancer Therapy
Box 37: Quick Facts - QS-21
Box 38: Quick Facts - Talabostat
Box 39: Quick Facts - SB 249553
Box 40: Quick Facts - GVAX
Box 41: Agreement Japan Tobacco and Cell Genesys
Box 42: Predicted launch of GVAX
Box 43: Quick Facts - GV 1001
Box 44: Quick Facts - Dexosome
Box 45: Important Milestones and License Fees
Box 46: Quick Facts - Uvidem
Box 47: Agreements Between Sanofi-Aventis and IDM
Box 48: Quick Facts - NY-ESO-1 ISCOMS
Box 49: NY-ESO-1 and ISCOMATRIX
Box 50: Quick Facts - NovoVac-M1
Box 51: Quick Facts - Oxxon vaccine
Box 52: Quick Facts - Therion' s Melanoma Vaccine
Box 53: Quick Facts - ImmunoVEX trimelan
Box 54: Quick Facts - OncoVEX GM-CSF
Box 55: Quick Facts - ZADAXIN
Box 56: Developmental History Thymosin alpha1
Box 57: Quick Facts - Alvac-Mage1/Mage3
Box 58: Quick Facts - iboctadekin
Box 59: Quick Facts - PF-3512676
Box 60: Quick Facts - BAY-504798
Box 61: Quick Facts - EMD-273063
Box 62: Quick Facts - Sorefenib
Box 63: Quick Facts - Vitaxin
Box 64: Quick Facts . Bevacizumab
Box 65: Quick Facts - PI88
Box 66: Quick Facts - Didemnin B
Box 67: Quick Facts - KOS 953
Box 68: Quick Facts - Pivanex
Box 69: Quick Facts - Karenitecin
Box 70: Company Statement
Box 71: Quick Facts - Lomeguatrib

List of Figures

Box 72: Quick Facts - PD 0325901
Box 73: Quick Facts - SB 715992
Box 74: Quick Facts - INO 1001
Box 75: Quick Facts - CP 4055
Box 76: Quick Facts - AP 12009
Box 77: Quick Facts - Ecromeximab
Box 78: Quick Facts - ILX 651
Box 79: Quick Facts - Kahalalide F
Box 80: Quick Facts - ABX MA1
Box 81: Quick Facts - MJV 101
Box 82: Quick Facts - Russian Melanoma Vaccine
Box 83: Quick Facts - N-Acetyl-GM3 ganglioside
Box 84: Quick Facts - F 50040
Box 85: KpOmpA Technology

List of Figures

Figure 1: Distribution of Compound Types Among Apoptopic Drugs
Figure 2: Primary Sub-cellular Localization of Drug Targets